ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0877 • ACR Convergence 2020

    Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib

    Uta Kiltz1, Joachim Sieper2, Atul Deodhar3, Patrick Zueger4, In-Ho Song4, Naijun Chen4 and Désirée van der Heijde5, 1Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Herne, Germany, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Oregon Health & Science University, Portland, OR, 4AbbVie Inc., North Chicago, IL, 5Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Upadacitinib (UPA) has been shown to be effective and well tolerated in patients with active ankylosing spondylitis (AS) [1]. However, improvements in global functioning…
  • Abstract Number: 0876 • ACR Convergence 2020

    Gender Differences in Baseline Clinical Characteristics Among Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis: Data from 3 Randomized Ixekizumab Controlled Trials

    Marina Magrey1, Kurt de Vlam2, Rebecca Bolce3, Soyi Liu-Leage4, Danting Zhu4, Theresa Hunter3, David Sandoval3 and Irene van der Horst-Bruinsma5, 1Case Western Reserve University School of Medicine, Cleveland, OH, 2Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, 3Eli Lilly and Company, Indianapolis, 4Eli Lilly and Company, Indianapolis, IN, 5Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to placebo in the treatment of patients with axial spondyloarthritis (axSpA) (Dougados M et…
  • Abstract Number: 0882 • ACR Convergence 2020

    Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial

    Frank Behrens1, Philipp Sewerin2, Eugenio De Miguel3, Yusuf Patel4, Anastas Batalov5, Eva Dokoupilova6, Christine Kleinmond7, Effie Pournara8, Ankita Shekhawat9, Claudia Jentzsch10, Annette Wiedon11 and Xenofon Baraliakos12, 1CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 2Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf, Duesseldorf, Germany, 3Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, 4Hull University Teaching Hospitals, Hull East Yorkshire, United Kingdom, 5Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 6MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, 7ClinProject GmbH, Eurasburg, Germany, 8Novartis Pharma AG, Basel, Switzerland, 9Novartis Healthcare Private Limited, Hyderabad, Telangana, India, 10Novartis Pharma GmbH, Nuremberg, Germany, 11Novartis Pharma GmbH, Nurnberg, Germany, 12Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Enthesitis is a key feature of all types of spondyloarthritis (SpA) that substantially contributes to the overall burden of disease. Inhibition of the key…
  • Abstract Number: 0881 • ACR Convergence 2020

    Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study

    Irene van der Horst-Bruinsma1, Rianne van Bentum1, Frank Verbraak2, Thomas Rath3, James Rosenbaum4, Bengt Hoepken5, Oscar Irvin-Sellers6, Thomas Kumke5, Lars Bauer5 and Martin Rudwaleit7, 1Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 2Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 3St Franziskus-Hospital, Münster, Germany, 4Oregon Health & Science University, Portland, OR, 5UCB Pharma, Monheim am Rhein, Germany, 6UCB Pharma, Slough, United Kingdom, 7Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany

    Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant burden.1…
  • Abstract Number: 0887 • ACR Convergence 2020

    Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network

    Simon Helfgott1, Jeremy Broestl2, Kent Kwas Huston3, Deepali Rane2, Jasvinder Singh4, Nehad Soloman5 and Colin Edgerton6, 1BWH- HMS, Boston, MA, 2Trio Health, Louisville, CO, 3Kansas City Physician Partners, Kansas City, MO, 4University of Alabama at Birmingham, Birmingham, AL, 5Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, 6Articularis Healthcare, Summerville, SC

    Background/Purpose: Systemic lupus erythematosus (SLE) treatments include steroids, antimalarials, immunosuppressants and/or biologics, though the use of biologics has been reported as minimal in claim-based studies…
  • Abstract Number: 0889 • ACR Convergence 2020

    Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies

    Christopher Ritchlin1, Alan Kivitz2, Peter Nash3, Renato Calheiros4, Xiangyi Meng5, Corine Gaillez6, Bruce Kirkham7 and Iain McInnes8, 1Department of Medicine, University of Rochester Medical Center, Rochester, NY, 2Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, 3School of Medicine Griffith University, Brisbane, Queensland, Australia, 4Novartis Pharmaceuticals Corporation, Hoboken, NJ, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Novartis Pharma AG, Basel, Switzerland, 7Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, 8Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) can progress quickly and lead to irreversible damage within 2 years of initial assessment if not treated.1 Secukinumab (SEC), a selective…
  • Abstract Number: 0884 • ACR Convergence 2020

    Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Patrick Zueger4 and Alexis Ogdie5, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…
  • Abstract Number: 0879 • ACR Convergence 2020

    Application of Treat-to-Target in Axial Spondyloarthritis in Daily Practice

    Esther Beckers1, Annelies Boonen1, Casper Webers1, Peter Ten Klooster2, Harald Vonkeman2, Monique Efde3 and Astrid van Tubergen4, 1Maastricht University Medical Center, Maastricht, Netherlands, 2University of Twente, Enschede, Netherlands, 3VieCuri Medical Center, Venlo, Netherlands, 4Maastricht University Medical Center, Maastricht

    Background/Purpose: Treat-to-target (T2T) management strategies in inflammatory rheumatic diseases aim to prevent damage and improve overall functioning and health by treating patients towards a predefined…
  • Abstract Number: 0892 • ACR Convergence 2020

    Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis

    Sergio Schwartzman1, David Sandoval2, Andris Kronbergs2, Jeffrey Lisse3, Himanshu Patel3, Wen Xu3, Soyi Liu-Leage3, Marina Magrey4, Helena Marzo-Ortega5 and Denis Poddubnyy6, 1Weill Cornell Medical College, New York, NY, 2Eli Lilly and Company, Indianapolis, 3Eli Lilly and Company, Indianapolis, IN, 4Case Western Reserve University School of Medicine, Cleveland, OH, 5The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, 6Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in the treatment of the axial spondyloarthritis (axSpA) spectrum  (ankylosing spondylitis and…
  • Abstract Number: 0895 • ACR Convergence 2020

    Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19-Subunit of Interleukin-23, on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies

    Dennis McGonagle1, Iain McInnes2, Atul Deodhar3, Georg Schett4, Philip Mease5, May Shawi6, Shelly Kafka7, Chetan Karyekar8, Alexa Kollmeier9, Elizabeth Hsia10, Xie Xu11, Shihong Sheng12, Prasheen Agarwal12, Bei Zhou12, Christopher Ritchlin13 and Proton Rahman14, 1The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, 2Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 3Oregon Health & Science University, Portland, OR, 4Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 5Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 6Janssen Global Services, LLC, Toronto, ON, Canada, 7Janssen Scientific Affairs, LLC, Horsham, PA, 8Janssen Global Services, LLC, Horsham, PA, 9Janssen Research & Development, LLC, La Jolla, CA, 10Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, 11Janssen Research & Development, LLC, San Marcos, CA, 12Janssen Research & Development, LLC, Spring House, PA, 13Department of Medicine, University of Rochester Medical Center, Rochester, NY, 14Memorial University of Newfoundland, Department of Medicine, St John's, Canada

    Background/Purpose: Guselkumab (GUS), a novel monoclonal antibody that specifically binds to the p19-subunit of IL-23, demonstrated efficacy in the Ph 3 DISCOVER-1 (D1) & DISCOVER‑2…
  • Abstract Number: 0896 • ACR Convergence 2020

    Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs

    Iain McInnes1, William Tillett2, Philip Mease3, Kurt de Vlam4, Louis Bessette5, Ralph Lippe6, Anna Maniccia7, Patrick Zueger7, Dai Feng7, Koji Kato8 and Andrew Östör9, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, 3Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 4Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, 5Laval University, Quebec, Canada, 6AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 7AbbVie Inc., North Chicago, IL, 8AbbVie Inc, North Chicago, IL, 9Cabrini Medical Center, Monash University, Malvern, Victoria, Australia

    Background/Purpose: Pain is a dominant symptom of psoriatic arthritis (PsA), and pain reduction is a priority for patients (pts) that is often assessed in clinical…
  • Abstract Number: 0891 • ACR Convergence 2020

    Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2

    Kristian Reich1, Jan Dutz2, Peter Foley3, Diamant Thaçi4, Ron Vender5, Michael Song6, Megan Miller6, Yin Yu6, Shu Li7, Yaung-Kaung Shen6 and April W. Armstrong8, 1Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany, 2Vancouver General Hospital, Vancouver, Canada, 3University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc, Carlton, Australia, 4Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 5McMaster University, Hamilton, Canada, 6Janssen Research & Development, LLC, Spring House, 7Janssen Scientific Affairs, LLC, Horsham, 8Keck School of Medicine of University of Southern California, Los Angeles, CA

    Background/Purpose: Guselkumab (GUS), a fully human monoclonal antibody, selectively binds and blocks IL-23. VOYAGE 1 and VOYAGE 2 are two ongoing Phase 3, randomized, double-blind,…
  • Abstract Number: 0899 • ACR Convergence 2020

    Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial

    Denis Poddubnyy1, Effie Pournara2, Agnieszka Zielinska3, Asta Baranauskaite4, Alejandro Muñoz Jiménez5, Sanchayita Sadhu6, Barbara Schulz2, Michael Rissler2, Chiara Perella2 and Helena Marzo-Ortega7, 1Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3Medycyna Kliniczna, Warszawa, Poland, 4Lithuanian University of Health Sciences, Kaunas, Lithuania, 5H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, 6Novartis Healthcare Private Limited, Hyderabad, Telangana, India, 7The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom

    Background/Purpose: SKIPPAIN (NCT03136861) is the first randomized controlled study involving a biological disease modifying antirheumatic drug, with spinal pain as the primary endpoint as early…
  • Abstract Number: 0894 • ACR Convergence 2020

    Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study

    Stanley Cohen1, Justus Fiechtner2, Philip Mease3, Jeffrey Kaine4, Arthur Kavanaugh5, Yi-Lin (Irene) Cheng6, Claire Chou6, Ting-Ying Cheng7, Shih-Yao Lin6 and Mark Genovese8, 1University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, 2Michigan State University, Grand Rapids,, MI, 3Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 4Sarasota Arthritis Research Center, Sapphire, NC, 5UC San Diego Health System, San Diego, CA, 6AltruBio, Taipei, Taiwan (Republic of China), 7AltruBio, Redwood City, CA, 8Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.…
  • Abstract Number: 0786 • ACR Convergence 2020

    A Combination of Dimensionality Reduction Techniques Reveals Novel HLA-DR+ ‘Candidate’ Antigen-Presenting Cell Subsets (cAPC) in Patients with Rheumatoid Arthritis (RA)

    Christian Geier1, Jon Giles1, Samantha Gaines2, Christopher Depender1, Joan Bathon1 and Robert Winchester1, 1Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 2Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York

    Background/Purpose: The presentation of MHC-peptide complexes to T lymphocytes via antigen-presenting cells (APC) is a crucial step in the initiation of immune responses. Dendritic cells…
  • « Previous Page
  • 1
  • …
  • 684
  • 685
  • 686
  • 687
  • 688
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology